Helicobacter pylori eradication has no effect on metabolic and inflammatory parameters.
BACKGROUND
An increased risk in coronary heart disease associated with Helicobacter pylori (H. pylon) appears to be partially mediated by modifications of the atherogenic lipoprotein and inflammatory parameters. We conducted a controlled trial aimed at evaluating the changes of metabolic and inflammatory parameters after H. pylon eradication.


METHODS
We included in the study 169 patients with H. pylori infection and conducted a retrospective longitudinal survey of 87 subjects (76 men, 11 women) who received treatment for H. pylon eradication and 82 control subjects (63 men, 19 women) who did not receive treatment. We compared pre- and posteradication (one year after) the metabolic and inflammatory parameters, such as blood sugar, lipid profiles, insulin resistance, white blood cell count and C-reactive protein.


RESULTS
No significant changes from the baseline in metabolic and inflammatory parameters within each group were observed. Changes in the serum levels of metabolic and inflammatory parameters were similar between the two groups.


CONCLUSIONS
Metabolic and inflammatory parameters, including blood sugar, lipid profiles, insulin resistance, white blood cell count and C-reactive protein, were not changed after H. pylori eradication treatment. H. pylori eradication has no effect on metabolic and inflammatory parameters.
Park
Seung Ha
SH
Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jeon
Woo Kyu
WK
Kim
Sang Hoon
SH
Kim
Hong Joo
HJ
Park
Dong Il
DI
Cho
Yong Kyun
YK
Sung
In Kyung
IK
Sohn
Chong Il
CI
Kim
Byung Ik
BI
Keum
Dong Keuk
DK
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents; D016022:Case-Control Studies; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D005753:Gastric Mucosa / Q000473:pathology; D005756:Gastritis / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology*; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D018836:Inflammation Mediators / Q000032:analysis / Q000378:metabolism; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011336:Probability; D011379:Prognosis; D012016:Reference Values; D012189:Retrospective Studies; D018570:Risk Assessment
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D018836:Inflammation Mediators